Davide Rossi

Has grant

Associate Professor of Medicine

Università della Svizzera Italiana (USI)
Country flagSwitzerland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Oncogenic perturbations of the non-coding regulatory genome in classic Hodgkin lymphoma

Open Date: 2024-05-01

Close Date: 2028-04-01

Grant: Close

Dynamic risk profiling for the identification of patients with high-risk diffuse large B-cell lymphoma

Open Date: 2024-04-01

Close Date: 2026-03-01

Grant: Close

Finanziamento Ricercatori Senior

Open Date: 2024-01-01

Close Date: 2024-12-01

Grant: Open

Multilayer taxonomy of nodal marginal zone lymphoma

Open Date: 2024-01-01

Close Date: 2026-12-31

Grant: Close

Uncovering the pathophysiology and vulnerability of minimal residual disease persisting under ventoclax in patients with chronic lymphocytic leukemia

Open Date: 2023-05-01

Close Date: 2025-04-01

Articles (89)

Cyclin-dependent kinase 9 (CDK9) drives transcriptional elongation and supports the expression of short-lived oncogenic and anti-apoptotic proteins such as MYC and MCL1. PRT2527 is a potent, selective CDK9 inhibitor currently in early clinical development. We evaluated its preclinical activity in marginal zone lymphoma (MZL) models, including cell lines with acquired resistance to BTK, PI3K, and BCL2 inhibitors. Short exposure (4 hours) to PRT2527 produced nanomolar cytotoxicity across all tested MZL cell lines, with efficacy maintained in resistant derivatives. Transcriptomic profiling of VL51 cells showed broad gene repression, including MYC, IRF4, NF-κB-related genes, and MCL1, alongside increased expression of HLA class II genes. Moreover, comparison with additional CDK inhibitors revealed a similar transcriptional repression signature, underscoring a conserved CDK-dependent regulatory network. Protein analyses confirmed rapid depletion of MCL1, MYC, RNA polymerase II, and IRF4. Flow cytometry validated increased HLA class II and decreased HLA class I surface expression. Combination studies demonstrated additive to synergistic effects with BTK inhibition (ibrutinib) or dual PI3K/BCL2 inhibition (copanlisib plus venetoclax), independent of baseline drug sensitivity. Mechanistically, these combinations may enhance apoptosis by concurrently suppressing survival signaling and transcriptional addiction. Analysis of patient samples revealed high CDK9 expression, further supporting the biological relevance and therapeutic rationale for targeting CDK9 in this disease. Our findings support the development of CDK9-based combination strategies for relapsed/refractory MZL and other B-cell malignancies, with an additional potential for integration with immunotherapies. Key Points CDK9 inhibitor PRT2527 kills marginal zone lymphoma cells, regardless of whether they are resistant to other targeted drugs. PRT2527 boosts the effects of BTK, PI3K, and BCL2 inhibitors and alters immune-related gene expression. Draft of graphical abstract

Year:

2026

Year:

2025

Background BTK and BCL2 represent key therapeutic targets in B-cell lymphomas, including marginal zone lymphoma (MZL). Here, we evaluated the novel BTK degrader BGB-16673, and the second-generation BCL2 inhibitor sonrotoclax in a panel of MZL cell lines, including models with acquired resistance to BTK, BCL2 and PI3K inhibitors, as single agents and in combination. Methods Cytotoxicity, transcriptomic changes, apoptosis, and protein expression were assessed for BGB-16673 alone and in combination with venetoclax, sonrotoclax, bendamustine, selinexor, lenalidomide, and tazemetostat. Results BGB-16673 demonstrated single-agent activity in selected MZL cell lines, inducing BTK degradation and transcriptional repression of BCR signaling and MYC targets. Its transcriptional and phenotypic effects overlapped with those of zanubrutinib but also included specific modulation of oxidative phosphorylation genes. Combination studies revealed that BGB-16673 synergized with other targeted agents, achieving the best results with sonrotoclax, venetoclax, bendamustine, lenalidomide, and rituximab. The mechanism of action of the combination with the BCL2 inhibitors was further evaluated. The combination with sonrotoclax consistently enhanced apoptosis across MZL models, outperforming venetoclax in potency in most cell lines. Sonrotoclax showed over 10-fold higher activity than venetoclax in three MZL lines and demonstrated synergistic interaction with BGB-16673. Mechanistically, the combination leads to BTK degradation and modulation of anti-apoptotic proteins such as BCL2, MCL1, and BCL-XL. Conclusion Our findings underscore the potential of BGB-16673 as a therapeutic agent, both as a monotherapy and in combination regimens, for treating MZL patients. Additionally, the results also identify the second-generation BCL2 inhibitor sonrotoclax as another drug to be explored in the same patient populations.

Year:

2025

B-cell receptor (BCR) signaling is a key therapeutic target in B-cell lymphomas, and Bruton tyrosine kinase inhibitors (BTKi) have demonstrated clinical efficacy in marginal zone lymphoma (MZL). However, the rate of complete remissions is relatively low, and resistance remains a significant clinical challenge, underscoring the need for novel combination strategies. To identify compounds that enhance the activity of BTKi and overcome resistance, we conducted a high-throughput screen of 1,695 compounds using a previously developed MZL model of acquired resistance to BTK and PI3K inhibitors derived from the Karpas1718 cell line. Thirty-three compounds showed single-agent anti-proliferative activity in the nanomolar range, both in the Karpas1718-resistant and parental cells. Based on their clinical potential in combination with BTKi, seven compounds were selected for further validation. The polo-like kinase 1 (PLK1) inhibitor rigosertib emerged as a top candidate, showing strong activity in both parental and BTKi-resistant cell lines. Combination treatment of rigosertib and BTKi zanubrutinib resulted in broad transcriptomic changes, characterized by the downregulation of pathways involved in B-cell activation, proliferation, and BCR signaling. Mechanistically, the combination reduced phosphorylation of key BCR pathway components and inhibited NF-κB nuclear translocation. These findings suggest that PLK1 inhibition can overcome BTKi resistance by further inhibiting BCR signaling through the canonical NF-κB pathway. Therefore, the dual pharmacological inhibition of BTK and PLK1 is a promising therapeutic approach for patients with MZL and warrants further preclinical and clinical investigations.

Year:

2025

Background: CXCR4 is a chemokine receptor frequently implicated in the pathogenesis and treatment resistance of B-cell lymphomas and other tumor types. Thus, CXCR4 targeting is explored using various approaches, including small molecules, antibodies, and short peptides. Here, we investigated the antitumor effects of the CXCR4 pharmacological inhibition with the synthetic peptides SPX5551 and balixafortide, as single agents and in combination, in various B-cell lymphoma models. Methods: Binding modalities were assessed via molecular docking and simulation. In vitro assays evaluated single-agent and combinatorial effects of CXCR4 antagonists with BTK, PI3K, and conventional therapies across 20 lymphoma cell lines, including models with acquired resistance. Transcriptomic analyses and mechanistic studies elucidated the pathways modulated by combined CXCR4 and BTK inhibition. Results: Structural modeling confirmed similar CXCR4 binding modes for SPX5551 and balixafortide. SPX5551 displayed minimal single-agent activity but restored sensitivity to BTK and PI3K inhibitors in resistant marginal zone lymphoma (MZL) models. Across mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL) models, SPX5551 enhanced the efficacy and/or potency of ibrutinib, copanlisib, rituximab, and R-CHOP. In MCL, co-treatment with SPX5551 and ibrutinib synergistically induced apoptosis, inhibited NF-κB and AKT signaling, and led to broader transcriptomic repression of tumor-promoting pathways compared to either agent alone. Conclusions: Although CXCR4 inhibitors alone show limited cytotoxicity, their combination with standard and targeted therapies significantly enhances anti-lymphoma effects, particularly in drug-resistant settings. These findings provide a strong rationale for clinical evaluation of CXCR4 blockade as a combinatorial strategy in B-cell lymphomas.

Year:

2025

Introducing Bruton’s tyrosine kinase (BTK) inhibitors has significantly improved outcomes for patients with B-cell malignancies and autoimmune disorders. However, resistance, either primary or acquired, remains a major clinical challenge. To better understand the underlying resistance mechanisms to BTK inhibitors, we established an ibrutinib-resistant model from a patient-derived splenic marginal zone lymphoma (MZL) cell line (VL51) through prolonged drug exposure. Resistant cells exhibited a 15-fold increase in ibrutinib’s IC50, along with distinct morphological changes, mitochondrial activation, and cross-resistance to covalent, non-covalent BTK inhibitors and BTK degraders. Integrated transcriptomic, epigenomic, and proteomic analyses identified overexpression and secretion of IL-16 as a key feature of resistance, driven by chromatin remodeling and activation of the FLI1 transcription factor. IL-16 conferred ibrutinib resistance via CD9-mediated activation of the NF-κB and AKT signaling pathways and was found to be elevated in the serum of ibrutinib-refractory CLL patients. Functional studies showed that targeting the IL-16/CD9 axis using neutralizing antibodies or CD9-binding peptides restored sensitivity to BTK inhibitors and R-CHOP chemotherapy in MZL, mantle cell lymphoma, and diffuse large B-cell lymphoma models. These findings reveal a novel, targetable resistance mechanism with potential therapeutic implications for overcoming BTK inhibitor resistance in B-cell lymphomas.

Year:

2025

Multi-omics analyses. Output tables of the moderated t-tests comparing transcriptome, microRNA and methylation profiles of resistant and parental. Output results of Gene Set Enrichment Analysis comparing GEP data of resistant and parental.

Year:

2025

Levels of p-AKT (A, top) and p-ERK (B, bottom) were determined by phospho-flow cytometry upon 1µM of idelalisib. Density plots show the median MFI values of two replicates, negative control (dotted black), parental (grey), resistant (red). (B) Images on the left show the expression of pRELA by immunofluorescence upon 1µM of idelalisib (right) or control (DMSO, left) in parental and resistant (4hr exposure). Boxplot on the right represents the protein quantification from the immunofluorescence experiments. Data derived from two independent experiments. Three representative fields were evaluated from each independent experiment. P-values from Welch Two Sample test performed on mean MFI values.

Year:

2025

Cell viability was evaluated by MTT assay (72h). Karpas1718 parental (A) or resistant (B) were exposed to DMSO (control, black) or decitabine (100nM, red), given concomitantly (continuous lines) or 72 hours before idelalisib (pre DMSO in dashed black or pre decitabine in dashed red). Error bars correspond to standard deviation of the mean. Data derived from two independent experiments. Statistically significant differences were evaluated by moderated t-test comparing each treatment to control (DMSO).

Year:

2025

Ridgeplot on surface levels of ERBB4 by FACS in Karpas1718 resistant cells upon genetic silencing (siRNA) of ERBB2 (yellow), ERBB4 (red) or concomitant ERBB2 and ERBB4 (brown). Silencing control in grey and negative control in black. Data derived from two independent experiments. Statistically significant differences (p

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (42)

Kikkeri N Naresh

Section Head of Pathology & Professor

University of Washington

UNITED STATES
View details

ANASTASIOS STATHIS

Head of Research Service and Scientific Head Clinical Trial Unit

Istituto Cantonale di Patologia

SWITZERLAND
View details

Javeed Iqbal

Professor, Odeth E. Wall Centennial Professor of Oncology

University of Nebraska Medical Center

UNITED STATES
View details

Chris Bacon

Clinical Senior Lecturer/Consultant

Newcastle University

UNITED KINGDOM
View details

Kieron Dunleavy

Director

Georgetown University

UNITED STATES
View details

Jennifer Brown

Worthington and Margaret Collette Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES
View details

Carmelo Carlo‐Stella

IRCCS Humanitas Research Hospital

ITALY
View details

Davide F. Robbiani

Full Professor

Università del Salento

SWITZERLAND
View details

Seiichi Kato

Professor

Saga University

JAPAN
View details

Francesca Romana Mauro

-

ITALY
View details

Jan Lukas Bögeholz

University Hospital of Zurich

SWITZERLAND
View details

Karan Kathuria

Stanford University

UNITED STATES
View details

Lorenzo Leoncini

Docenti di ruolo di Ia fascia

University of Siena

ITALY
View details

Jan‐Michel Heger

-

GERMANY
View details

Brian Walker

Professor

University of Miami

UNITED STATES
View details

Giulio Sartori

Università della Svizzera Italiana (USI)

SWITZERLAND
View details

Pedro Farinha

Clinical Professor

The University of British Columbia

CANADA
View details

Adalgisa Condoluci

Institute of Cancer Research

SWITZERLAND
View details

Catalina Amador

Professor of Pathology

University of Miami Health System

UNITED STATES
View details

Andrea Cavalli

Group Leader

Institute for Research in Biomedicine

SWITZERLAND
View details

Emanuele Zucca

University of Bern

SWITZERLAND
View details

John Choi

The University of Alabama

UNITED STATES
View details

Sara Napoli

National Institute of Oncology

SWITZERLAND
View details

Justin Ferdinandus

University Hospital Bonn

GERMANY
View details

Afua Adjeiwaa Mensah

-

SWITZERLAND
View details

Alan Ramsay

King’s College London

UNITED KINGDOM
View details

Reuben M. Tooze

Professor

University of Leeds

UNITED KINGDOM
View details

maria ilaria del principe

Associate Prof

UNIVERSITY TOR VERGATA

ITALY
View details

Federico Simonetta

-

SWITZERLAND
View details

Emanuele Pravatà

Assitant Professor

University “G. d’Annunzio” of Chieti-Pescara

ITALY
View details

Sarah E. Coupland

Personal Chair

University of Liverpool

UNITED KINGDOM
View details

Vaskar Saha

The University of Manchester

UNITED KINGDOM
View details

Vittorio Limongelli

Full Professor

Università del Salento

SWITZERLAND
View details

Alexandar Tzankov

Head Histopathology and Autopsy

University Hospital Basel

SWITZERLAND
View details

Manel Esteller

Group Leader, Cancer Epigenetics Group

Josep Carreras Leukaemia Research Institute

SPAIN
View details

Stefano Luminari

Docenti di ruolo di Ia fascia

University of Modena and Reggio Emilia

ITALY
View details

qiang pan-hammarstrom

Professor, head of the Immunology Division

Karolinska University Hospital

SWEDEN
View details

Ondrej Havranek

Charles University

CZECH REPUBLIC
View details

Bastian von Tresckow

University of Cologne

GERMANY
View details

Ralf Trappe

Head of department

-

GERMANY
View details

Mohammad Shahrokh Esfahani

Assistant Professor

Stanford University

UNITED STATES
View details

Manuel Castro de Moura

Head of Bioinformatics Unit

Josep Carreras Leukaemia Research Institute

SPAIN
View details